Tuesday 13 October 2026 Export EDIT’s income statement to Excel — free account

Editas Medicine, Inc.

Editas Medicine, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $40.5 million, up 25.4% from fiscal 2024. In the quarter to June 2026, revenue grew 232.3%, EPS grew 76.2% and free cash flow grew 40.7%, each against the same quarter a year earlier.

2.47 0.28 −10.18%

Follow EDIT

Alert me

Market cap: $422.3M
P/E: 0.0×
Fwd P/E: −2.7×
Dividend yield: —
F-score: 2/9
Altman Z: −13.39
Beneish M: −2.46
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 0.11

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	3	—	—	3	—	—	3	1	1	3	—

Insider Ownership 0.00%

Capital & Financial Ratios $m

Market Cap 422.34

Revenue 47.01

Net Income (73.95)

Free Cash Flow (120.28)

Net Debt (211.64)

Current Ratio 3.19

Debt/Equity 0.00

P/E ratio 0.00

Fwd P/E (2.71)

P/S ratio 6.98

P/B ratio 3.12

Past 5Y EPS Growth —

This Y EPS Growth 56.83%

Next Y EPS Growth 8.61%

Next Y revenue growth (36.35%)

Next 5Y EPS Growth 25.35%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 19.48%

10-year low 10-year high

P/B against its own 10 years 36.69%

10-year low 10-year high

EV/Sales against its own 10 years 13.33%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2025	Powerpack
2024	Powerpack
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2017	Powerpack

predictions special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	323	270	147	212
Receivables	10	16	15	3
Inventory	—	—	—	—
Other	—	—	—	—
	341	289	164	218

	2023	2024	2025	Q'26
Payables	8	5	3	5
ST’ Debt	—	—	—	—
Other	—	5	5	8
	63	77	46	68

Compound Annual Growth %

	10y	5y	3y
Sales	37.90%	(14.89%)	27.15%
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	(13.53%)	(41.36%)	(57.71%)

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	3	12	—	—	—
’25	5	4	8	25	41
’24	1	1	0	31	32
’23	10	3	5	60	78
’22	7	6	0	7	20
’21	6	0	6	12	26
’20	6	11	63	11	91

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(23)	(30)	—	—	—
’25	(48)	(50)	(31)	(36)	(165)
’24	(50)	(57)	(53)	(51)	(210)
’23	(36)	(39)	(35)	(22)	(132)
’22	(49)	(38)	(48)	(42)	(177)
’21	(49)	(39)	(41)	(35)	(164)
’20	(54)	(31)	(55)	(40)	(180)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(23)	(30)	—	—	—
’25	(48)	(50)	(31)	(36)	(166)
’24	(52)	(61)	(56)	(51)	(219)
’23	(38)	(40)	(36)	(24)	(137)
’22	(51)	(38)	(49)	(43)	(181)
’21	(50)	(42)	(43)	(37)	(172)
’20	(56)	(33)	(57)	(41)	(187)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.26)	(0.15)	—	—	—
’25	(0.92)	(0.63)	(0.28)	(0.06)	(1.80)
’24	(0.76)	(0.82)	(0.75)	(0.55)	(2.88)
’23	(0.71)	(0.56)	(0.55)	(0.23)	(2.02)
’22	(0.74)	(0.78)	(0.81)	(0.88)	(3.21)
’21	(0.86)	(0.81)	(0.57)	(0.61)	(2.85)
’20	(0.69)	(0.43)	0.12	(1.00)	(1.98)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	12.43	13.12	17.80	19.00	14.01	26.51	8.21	6.08	1.16	0.91	Analyst estimates 2026–2028 Powerpack
	High	43.99	32.85	45.02	32.82	96.45	99.95	27.99	11.93	11.58	4.54
People
People	Employees	89	112	133	208	235	264	226	265	246	87
	Revenue/emp, $m	0.07	0.12	0.24	0.10	0.39	0.10	0.09	0.29	0.13	0.47
Income, $m
Income, $m	Revenue	6	14	32	21	91	26	20	78	32	41
	Gross margin, %	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00
	EBT	(97)	(120)	(110)	(134)	(116)	(193)	(220)	(153)	(237)	(160)
	EBT margin, %	(1,605.53)	(876.49)	(344.28)	(651.43)	(127.82)	(753.61)	(1,118.26)	(196.13)	(733.72)	(395.01)
	Net income	(97)	(120)	(110)	(134)	(116)	(193)	(220)	(153)	(237)	(160)
	Depreciation	1	3	3	3	4	7	6	1	0	4
Per share, $
Per share, $	Revenue	0.19	0.34	0.68	0.41	1.55	0.38	0.29	1.03	0.39	0.46
	Earnings	(3.02)	(2.98)	(2.33)	(2.68)	(1.98)	(2.85)	(3.21)	(2.02)	(2.88)	(1.80)
	Cash flow	(1.56)	(0.23)	(0.97)	(0.81)	(3.07)	(2.42)	(2.58)	(1.74)	(2.55)	(1.86)
	Capex	(0.11)	(0.05)	(0.10)	(0.12)	(0.12)	(0.12)	(0.06)	(0.06)	(0.11)	0.00
	Free cash flow	(1.67)	(0.28)	(1.07)	(0.93)	(3.19)	(2.54)	(2.64)	(1.80)	(2.66)	(1.87)
	Book value	4.18	5.16	5.01	5.25	6.72	8.19	5.25	4.60	1.63	0.31
	Shares, m	32	40	47	50	59	68	69	76	82	89
Valuation, ×
Valuation, ×	P/E	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	P/S	90.70	100.81	33.55	72.09	45.29	70.28	29.40	9.70	3.24	4.49
	P/B	4.08	6.65	4.54	5.64	10.44	3.24	1.61	2.17	0.78	6.67
	EV/Sales	65.89	79.27	23.01	51.40	41.21	51.98	13.58	5.98	(4.11)	1.67
	EV/FCF	(7.42)	(94.95)	(14.58)	(22.58)	(20.00)	(7.73)	(1.48)	(3.41)	0.61	(0.41)
Cash, $m
Cash, $m	Operating cash flow	(50)	(9)	(46)	(41)	(180)	(164)	(177)	(132)	(210)	(165)
	Capex	(3)	(2)	(5)	(6)	(7)	(8)	(4)	(5)	(9)	0
	Free cash flow	(54)	(11)	(50)	(47)	(187)	(172)	(181)	(137)	(219)	(166)
Balance, $m
Balance, $m	Working capital	154	295	339	404	361	460	297	278	212	118
	Total debt	35	33	32	23	19	16	33	—	—	—
	Net debt	(150)	(296)	(337)	(457)	(402)	(500)	(344)	(323)	(270)	(147)
	Shareholders’ equity	135	208	236	262	394	554	361	349	134	27
Returns, %
Returns, %	ROA	(51.37)	(39.95)	(27.71)	(28.79)	(21.45)	(30.80)	(36.99)	(30.24)	(56.40)	(60.61)
	ROIC	0.00	0.00	0.00	0.00	0.00	(224.39)	(860.78)	(406.90)	0.00	0.00
	ROE	(377.64)	(70.22)	(49.50)	(53.65)	(35.36)	(40.65)	(48.22)	(43.17)	(98.10)	(198.14)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
RZLT Rezolute, Inc.	$471.1M	— (loss-making)	—	—	n/m	+40.23% (above 0%: growing)	0.00%	0.00%	Compare
ENTX Entera Bio Ltd.	$462.4M	— (loss-making)	— (loss-making)	+200.00% (above 0%: growing)	n/m	−108.86% (below 0%: shrinking)	0.00%	0.00%	Compare
TECX Tectonic Therapeutic, Inc.	$456.1M	— (loss-making)	—	—	n/m	−46.69% (below 0%: shrinking)	0.00%	0.00%	Compare
CAPR Capricor Therapeutics, Inc.	$455.2M	— (loss-making)	— (loss-making)	−7.92% (below 0%: shrinking)	n/m	−72.88% (below 0%: shrinking)	100.00%	0.00%	Compare
PRTA Prothena Corporation plc	$453.8M	— (loss-making)	188×	−77.15% (below 0%: shrinking)	n/m	+44.64% (above 0%: growing)	100.00%	(2,089.21%)	Compare
DMAC DiaMedica Therapeutics, Inc.	$449.2M	— (loss-making)	— (loss-making)	—	n/m	−6.75% (below 0%: shrinking)	0.00%	0.00%	Compare
EDIT Editas Medicine, Inc.	$445.4M	— (loss-making)	— (loss-making)	+232.31% (above 0%: growing)	n/m	+40.72% (above 0%: growing)	100.00%	(156.05%)
PRTCY PureTech Health PLC Sponsored ADR	$424.0M	— (loss-making)	— (loss-making)	−44.60% (below 0%: shrinking)	+66.43% (above 0%: growing)	+19.27% (above 0%: growing)	2.83%	0.00%	Compare
SPRY ARS Pharmaceuticals, Inc.	$420.7M	— (loss-making)	— (loss-making)	+114.15% (above 0%: growing)	n/m	−53.69% (below 0%: shrinking)	61.83%	(182.62%)	Compare
Median of peers	$454.5M	—	—	−7.92%	—	−26.72%	1.42%	0.00%

All 614 Biotechnology stocks →

Editas Medicine, Inc. (EDIT) key facts

Strength: Editas Medicine, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $40.5 million, up 25.4% from fiscal 2024.
Editas Medicine, Inc. (EDIT) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
As of October 12, 2026, EDIT traded at $2.75, a market capitalization of $422.3 million.
Return on equity was −198.1% and debt-to-equity 0.00.
Its Piotroski F-score is 2 out of 9 and its Altman Z-score is −13.39 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.